https://www.live-feeds.com/feed/novo-s-ceo-called-ozempic-s-patent-cliff-the-elephant-in-the-room-yesterday-is-the-stock-still-a-buyContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novo-s-ceo-called-ozempic-s-patent-cliff-the-elephant-in-the-room-yesterday-is-the-stock-still-a-buyhttps://www.live-feeds.com/feed/novo-s-ceo-called-ozempic-s-patent-cliff-the-elephant-in-the-room-yesterday-is-the-stock-still-a-buy#u82491Thu, 24 Sep 2026 10:15:50 +0000Novo Nordisk is plotting its corporate future as upcoming semaglutide patent expirations loom large over the drugmaker. The company's chief executive officer addressed the patent cliff directly, acknowledging the challenge while setting ambitious targets to reassure investors. Novo Nordisk aims to introduce more than five blockbuster drugs by the year 2030. To bolster its drug pipeline against pending patent expirations, leadership is actively signaling potential mergers and acquisitions. Observers note that building market confidence remains a central task for management as the pharmaceu